EP2258402A3 - Getrocknete Zusammensetzung - Google Patents
Getrocknete Zusammensetzung Download PDFInfo
- Publication number
- EP2258402A3 EP2258402A3 EP10008828A EP10008828A EP2258402A3 EP 2258402 A3 EP2258402 A3 EP 2258402A3 EP 10008828 A EP10008828 A EP 10008828A EP 10008828 A EP10008828 A EP 10008828A EP 2258402 A3 EP2258402 A3 EP 2258402A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- dried composition
- stable
- trehalose
- absence
- serum albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9501040.1A GB9501040D0 (en) | 1995-01-19 | 1995-01-19 | Dried composition |
EP96900633A EP0871476B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose |
EP03002147A EP1308170B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete Blutfaktorzusammensetzung mit Trehalose |
EP08010169A EP1974741A1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96900633.7 Division | 1996-07-25 | ||
EP03002147.1 Division | 2003-02-03 | ||
EP08010169.4 Division | 2008-06-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2258402A2 EP2258402A2 (de) | 2010-12-08 |
EP2258402A3 true EP2258402A3 (de) | 2011-01-05 |
Family
ID=10768253
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10008828A Withdrawn EP2258402A3 (de) | 1995-01-19 | 1996-01-19 | Getrocknete Zusammensetzung |
EP03002147A Expired - Lifetime EP1308170B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete Blutfaktorzusammensetzung mit Trehalose |
EP08010169A Withdrawn EP1974741A1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung |
EP96900633A Expired - Lifetime EP0871476B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03002147A Expired - Lifetime EP1308170B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete Blutfaktorzusammensetzung mit Trehalose |
EP08010169A Withdrawn EP1974741A1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete, von Trehalose stabilisierte Blutfaktorzusammensetzung |
EP96900633A Expired - Lifetime EP0871476B1 (de) | 1995-01-19 | 1996-01-19 | Getrocknete zubereitung von bluttfaktoren, enthaltend trehalose |
Country Status (15)
Country | Link |
---|---|
US (2) | US6649386B2 (de) |
EP (4) | EP2258402A3 (de) |
JP (1) | JP3898221B2 (de) |
KR (1) | KR100417593B1 (de) |
CN (1) | CN1152713C (de) |
AT (2) | ATE245442T1 (de) |
AU (1) | AU704317B2 (de) |
CA (2) | CA2671383C (de) |
DE (2) | DE69629209T2 (de) |
DK (2) | DK1308170T3 (de) |
ES (2) | ES2202425T3 (de) |
GB (1) | GB9501040D0 (de) |
PT (2) | PT871476E (de) |
SI (1) | SI1308170T1 (de) |
WO (1) | WO1996022107A1 (de) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US6964771B1 (en) | 1995-06-07 | 2005-11-15 | Elan Drug Delivery Limited | Method for stably incorporating substances within dry, foamed glass matrices |
US6632648B1 (en) * | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
GB9616536D0 (en) * | 1996-08-06 | 1996-09-25 | Quadrant Holdings Cambridge | Co-amoxiclav dosage form |
AUPO871997A0 (en) * | 1997-08-25 | 1997-09-18 | Csl Limited | Dried biologically or therapeutically active preparations |
EP2921180B1 (de) * | 1999-02-22 | 2019-08-14 | University of Connecticut | Albuminfreie Faktor-VIII-Formulierungen |
JP4340151B2 (ja) * | 2001-08-10 | 2009-10-07 | 株式会社林原生物化学研究所 | トレハロース又はマルチトールと金属イオン化合物との会合物 |
US8541002B2 (en) | 2003-09-12 | 2013-09-24 | Agenus Inc. | Vaccine for treatment and prevention of herpes simplex virus infection |
EP1755652B1 (de) | 2004-03-19 | 2010-11-24 | Baxter International Inc. | Faktor ixa zur behandlung von blutungsstörungen |
ATE441669T1 (de) * | 2004-05-24 | 2009-09-15 | Genvault Corp | Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form |
KR100624013B1 (ko) | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
US8133484B2 (en) | 2006-12-15 | 2012-03-13 | Lifebond Ltd | Hemostatic materials and dressing |
CA2673260A1 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
EP1958618A1 (de) * | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
DK2222315T3 (da) * | 2007-12-21 | 2013-07-08 | Cangene Corp | Stabiliserede faktor-ix-formuleringer indeholdende trehalose |
SG187410A1 (en) * | 2007-12-28 | 2013-02-28 | Baxter Int | Recombinant vwf formulations |
US11197916B2 (en) | 2007-12-28 | 2021-12-14 | Takeda Pharmaceutical Company Limited | Lyophilized recombinant VWF formulations |
JP2012501681A (ja) | 2008-09-12 | 2012-01-26 | ジェンボールト コーポレイション | 生体分子の貯蔵および安定化のためのマトリックスおよび媒体 |
JP5781931B2 (ja) | 2008-10-21 | 2015-09-24 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 凍結乾燥した組換え型vwf製剤 |
KR101752508B1 (ko) | 2008-11-07 | 2017-06-29 | 백스터 인터내셔널 인코포레이티드 | 제8 인자 제형 |
CN102711853B (zh) | 2009-12-22 | 2015-05-20 | 生命连结有限公司 | 用于控制交联基质的性质的酶交联剂的改性 |
JP2014521084A (ja) * | 2011-07-13 | 2014-08-25 | デナトール アクティエボラグ | 液状生体試料の安定化法 |
CN102416171B (zh) * | 2011-12-06 | 2013-12-25 | 中国医学科学院输血研究所 | 高纯度凝血酶原复合物制品干热病毒灭活过程中的保护剂 |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
EP3082769B1 (de) * | 2013-12-19 | 2018-01-31 | Janssen Vaccines & Prevention B.V. | Verbesserte formulierungen für virosome |
DK3177317T3 (en) | 2014-08-04 | 2020-06-15 | Csl Ltd | Factor viii formulation |
EP3294324A1 (de) | 2015-05-13 | 2018-03-21 | Agenus Inc. | Impfstoffe zur behandlung und prävention von krebs |
CN107333750A (zh) * | 2017-06-11 | 2017-11-10 | 成都吱吖科技有限公司 | 一种长时血液细胞稳定剂 |
KR20210005646A (ko) | 2018-04-26 | 2021-01-14 | 아게누스 인코포레이티드 | 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법 |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
WO2022261716A1 (en) * | 2021-06-16 | 2022-12-22 | Exopharm Limited | Aqueous formulations for preservation of extracellular vesicles |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000196A1 (en) * | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0314095A1 (de) * | 1987-10-29 | 1989-05-03 | Rhone-Poulenc Rorer International (Holdings) Inc. | Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke |
EP0315968A1 (de) * | 1987-11-09 | 1989-05-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke |
EP0475409A2 (de) * | 1990-09-12 | 1992-03-18 | Lifecell Corporation | Verfahren und Vorrichtung zur Kryopräparation, trockene Stabilisierung und Rehydratisierung von biologischem Suspensionen |
WO1994007510A1 (en) * | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
WO1995001804A1 (en) * | 1993-07-05 | 1995-01-19 | Pharmacia Ab | A coagulation factor viii formulation |
WO1995007713A1 (en) * | 1993-09-13 | 1995-03-23 | Baxter International Inc. | Activated factor viii as a therapeutic agent and method of treating factor viii deficiency |
US6171825B1 (en) * | 1997-04-18 | 2001-01-09 | Bayer Corporation | Preparation of recombinant factor VIII in a protein free medium |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4361509A (en) | 1981-12-14 | 1982-11-30 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
US4495175A (en) * | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
FI86885C (fi) | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
EP0182448A3 (de) | 1984-08-24 | 1987-10-28 | Genetics Institute, Inc. | Verfahren zur Herstellung von Faktor VIII und verwandte Produkte |
US4758657A (en) * | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
US4806343A (en) * | 1986-03-13 | 1989-02-21 | University Of Southwestern Louisiana | Cryogenic protectant for proteins |
DE4111393A1 (de) * | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
US5288853A (en) * | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
WO1995003332A1 (en) * | 1993-07-23 | 1995-02-02 | Baxter International Inc. | Activated human factor viii and method of preparation |
US5955448A (en) * | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
EP2921180B1 (de) * | 1999-02-22 | 2019-08-14 | University of Connecticut | Albuminfreie Faktor-VIII-Formulierungen |
-
1995
- 1995-01-19 GB GBGB9501040.1A patent/GB9501040D0/en active Pending
-
1996
- 1996-01-19 ES ES96900633T patent/ES2202425T3/es not_active Expired - Lifetime
- 1996-01-19 DK DK03002147T patent/DK1308170T3/da active
- 1996-01-19 PT PT96900633T patent/PT871476E/pt unknown
- 1996-01-19 DE DE69629209T patent/DE69629209T2/de not_active Expired - Lifetime
- 1996-01-19 AT AT96900633T patent/ATE245442T1/de active
- 1996-01-19 CA CA2671383A patent/CA2671383C/en not_active Expired - Lifetime
- 1996-01-19 EP EP10008828A patent/EP2258402A3/de not_active Withdrawn
- 1996-01-19 DK DK96900633T patent/DK0871476T3/da active
- 1996-01-19 SI SI9630765T patent/SI1308170T1/sl unknown
- 1996-01-19 ES ES03002147T patent/ES2316658T3/es not_active Expired - Lifetime
- 1996-01-19 EP EP03002147A patent/EP1308170B1/de not_active Expired - Lifetime
- 1996-01-19 EP EP08010169A patent/EP1974741A1/de not_active Withdrawn
- 1996-01-19 DE DE69637749T patent/DE69637749D1/de not_active Expired - Lifetime
- 1996-01-19 WO PCT/GB1996/000119 patent/WO1996022107A1/en active IP Right Grant
- 1996-01-19 EP EP96900633A patent/EP0871476B1/de not_active Expired - Lifetime
- 1996-01-19 AT AT03002147T patent/ATE413885T1/de active
- 1996-01-19 CA CA002210872A patent/CA2210872C/en not_active Expired - Lifetime
- 1996-01-19 AU AU44540/96A patent/AU704317B2/en not_active Expired
- 1996-01-19 CN CNB961926600A patent/CN1152713C/zh not_active Expired - Lifetime
- 1996-01-19 KR KR1019970704891A patent/KR100417593B1/ko not_active IP Right Cessation
- 1996-01-19 PT PT03002147T patent/PT1308170E/pt unknown
- 1996-01-19 US US08/875,796 patent/US6649386B2/en not_active Expired - Lifetime
- 1996-01-19 JP JP52213396A patent/JP3898221B2/ja not_active Expired - Fee Related
-
2009
- 2009-02-13 US US12/371,459 patent/US7803911B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000196A1 (en) * | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
US4891319A (en) * | 1985-07-09 | 1990-01-02 | Quadrant Bioresources Limited | Protection of proteins and the like |
EP0314095A1 (de) * | 1987-10-29 | 1989-05-03 | Rhone-Poulenc Rorer International (Holdings) Inc. | Plasma- und Rekombinationsproteinformulierungen in einem Milieu hoher Ionenstärke |
EP0315968A1 (de) * | 1987-11-09 | 1989-05-17 | Rhone-Poulenc Rorer International (Holdings) Inc. | Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke |
EP0475409A2 (de) * | 1990-09-12 | 1992-03-18 | Lifecell Corporation | Verfahren und Vorrichtung zur Kryopräparation, trockene Stabilisierung und Rehydratisierung von biologischem Suspensionen |
WO1994007510A1 (en) * | 1992-10-02 | 1994-04-14 | Kabi Pharmacia Ab | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
WO1995001804A1 (en) * | 1993-07-05 | 1995-01-19 | Pharmacia Ab | A coagulation factor viii formulation |
WO1995007713A1 (en) * | 1993-09-13 | 1995-03-23 | Baxter International Inc. | Activated factor viii as a therapeutic agent and method of treating factor viii deficiency |
US6171825B1 (en) * | 1997-04-18 | 2001-01-09 | Bayer Corporation | Preparation of recombinant factor VIII in a protein free medium |
Non-Patent Citations (6)
Title |
---|
"AlphaNine SD / Alphanate / Pr ofilnine SD", INTERNET CITATION, XP002263525, Retrieved from the Internet <URL:http://www.alphather.com/products /ins_alhpa.htm> [retrieved on 19990719] * |
B. ROSER: "Trehalose drying: a novel replacement for freeze-drying", BIOPHARM., vol. 4, no. 8, 1991, pages 47 - 53, XP000569065 * |
BOEDEKER B G D: "Production processes of licensed recombinant factor VIII preparations", SEMINARS IN THROMBOSIS AND HEMOSTASIS 2001 UNITED STATES, vol. 27, no. 4, 2001, pages 385 - 394, XP002263524, ISSN: 0094-6176 * |
BUNDESVERBAND DE PHARMAZEUTISCHEN INDUSTRIE E.V. (ED.): "Rote Liste 1994", 1994, EDITIO CANTOR, AULENDORF/WÜRTT., DE, XP002263526 * |
COLACO C ET AL: "EXTRAORDINARY STABILITY OF ENZYMES DRIED IN TREHALOSE: SIMPLIFIED MOLECULAR BIOLOGY", BIO/TECHNOLOGY, NATURE PUBLISHING CO. NEW YORK, US, vol. 10, no. 9, 1 September 1992 (1992-09-01), pages 1007 - 1011, XP000568746, ISSN: 0733-222X * |
J.L. CLELAND, EDITOR: "ACS Symposium Series 567. Formulation and Delivery of Proteins and Peptides. Chapter 14.", 1994, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC, XP002002130 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2258402A3 (de) | Getrocknete Zusammensetzung | |
HUP0000474A3 (en) | Arylethenesulfonamide derivatives and drug composition containing the same | |
HUP9601566A2 (en) | Therapeutic tetrahydro-isoquinolin derivatives, their intermediates and pharmaceutical compositions containing the active component | |
CA2181172A1 (en) | Storage-stable prostaglandin compositions | |
AU8027291A (en) | Coated solid medicament form having releasability in large intestine | |
AU7702291A (en) | Dietary fiber, its process and physiologically active composition containing the same as an active ingredient | |
HUP9900881A3 (en) | 4,5-diaryl oxazole derivatives and pharmaceutical compositions containing them | |
AU6636598A (en) | Novel 3,4-dialkoxyphenyl derivatives and the use thereof | |
AU646942B2 (en) | 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides | |
PL320916A1 (en) | Derivatives of piperasino 2,5-dione as modulators of drug-fastness in respect to amny drugs | |
HUP9801256A3 (en) | 5'-deoxy-cytidine derivatives, preparation and use thereof and pharmaceutical compositions | |
AU3720193A (en) | Hydroisoindolines and hydroisoquinolines as psychotropic drugs | |
HUP9903459A3 (en) | Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same | |
AU5980590A (en) | 5-substituted 1,3,4-thiadizole derivatives, their preparation and their use as pesticides | |
USD370972S (en) | Decoy for whitetail deer | |
IL117806A0 (en) | 1,3-Dihydro-2h-imidazol-2-one derivatives their preparation and pharmaceutical compositions containing them | |
AU6944696A (en) | Novel phenylacetic acid derivatives and medicinal composition containing the same | |
AU1380397A (en) | Injectable pharmaceutical composition comprising ursodesoxycholic acid or tauroursodesoxycholic acid, strong base and tromethamol | |
IL124415A (en) | N, n'-bridged bisindolylmaleimides, their preparation and pharmaceutical compositions containing them | |
PL310146A1 (en) | Application of 1,4-dihydropyridino-3,5-dicarboxylic esters as drugs as well as novel active substances and drugs | |
AU4318397A (en) | Novel 2,4-dioxopyrrolidine and 2,4-dioxotetrahydrofuran derivatives and medicines containing the same as the active ingredient | |
CA2103666A1 (en) | Products containing verapamil and trandolapril | |
AU1939697A (en) | Physiologically active substances tkr1785's, process for the preparation thereof, and microbe | |
HUP9601918A3 (en) | N,n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate and pharmaceutical composition containing the same | |
PL313116A1 (en) | Application of n-alkalated 1,4-dihydropridinocarboxylic esters as drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
17P | Request for examination filed |
Effective date: 20100909 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1308170 Country of ref document: EP Kind code of ref document: P Ref document number: 1974741 Country of ref document: EP Kind code of ref document: P Ref document number: 0871476 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 47/26 20060101ALI20101129BHEP Ipc: A61K 38/37 20060101AFI20101129BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1147418 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20150924 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160205 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1147418 Country of ref document: HK |